Ernexa Therapeutics (ERNA) Current Deferred Revenue (2016 - 2025)
Historic Current Deferred Revenue for Ernexa Therapeutics (ERNA) over the last 14 years, with Q1 2025 value amounting to $5.3 million.
- Ernexa Therapeutics' Current Deferred Revenue rose 272275.13% to $5.3 million in Q1 2025 from the same period last year, while for Mar 2025 it was $5.3 million, marking a year-over-year increase of 272275.13%. This contributed to the annual value of $600000.0 for FY2023, which is N/A changed from last year.
- As of Q1 2025, Ernexa Therapeutics' Current Deferred Revenue stood at $5.3 million, which was up 272275.13% from $189000.0 recorded in Q2 2024.
- Over the past 5 years, Ernexa Therapeutics' Current Deferred Revenue peaked at $5.3 million during Q1 2025, and registered a low of $189000.0 during Q1 2024.
- Moreover, its 3-year median value for Current Deferred Revenue was $349000.0 (2023), whereas its average is $1.3 million.
- Examining YoY changes over the last 5 years, Ernexa Therapeutics' Current Deferred Revenue showed a top increase of 272275.13% in 2025 and a maximum decrease of 272275.13% in 2025.
- Ernexa Therapeutics' Current Deferred Revenue (Quarter) stood at $600000.0 in 2023, then plummeted by 68.5% to $189000.0 in 2024, then skyrocketed by 2722.75% to $5.3 million in 2025.
- Its Current Deferred Revenue stands at $5.3 million for Q1 2025, versus $189000.0 for Q2 2024 and $189000.0 for Q1 2024.